All In Biotech

Drug Trial Radar · NCT06277492

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Oral Doses of SUL-238 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Feb 19, 2024

Primary completion

Jul 11, 2025

Study completion Nov 27, 2025

Sponsor

Sponsor type
Industry
Collaborators
Sulfateq B.V.
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).

Conditions

  • Healthy Subjects

Interventions

  • Single ascending doses SUL-238Drug

    PART 1: SUL-238 single ascending doses

  • Single dose PlaceboDrug

    PART 1: Placebo single dose

  • Single dose SUL-238Drug

    PART 2: SUL-238 single dose for pharmacokinetics

  • Multiple ascending doses SUL-238Drug

    PART 3: SUL-238 multiple ascending doses

  • Multiple doses PlaceboDrug

    PART 3: Placebo multiple doses

  • 2000 mg SUL-238 single dose for pharmacokinetics (food effect)Drug

    PART 2B: 2000 mg single dose of SUL-238

  • Single dose placebo (food effect)Drug

    PART 2B: Placebo single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events as Measured by NCI-CTCAE criteriaTime frame: Up to day 29
  2. Incidence of Treatment-Emergent Adverse Events as Measured by Clinical Laboratory Measurements According to Established Clinical Normal RangesTime frame: Up to day 29
  3. Incidence of Treatment-Emergent Adverse Events as Measured by ECGTime frame: Up to day 29
  4. Incidence of Treatment-Emergent Adverse Events as Measured by physical examination and vital signsTime frame: Up to day 29
  5. Incidence of Treatment-Emergent Adverse Events as Measured by central nervous system (CNS) and autonomic nervous system (ANS) examination.Time frame: Up to day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erciyes University IKUM Center

    Kayseri, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.